A study to investigate how multiple oral doses of AZD2389 affect the pharmacokinetics of midazolam, caffeine, and bupropion in healthy participants

Trial Identifier:	D7930C00007
Sponsor:	AstraZeneca
Collaborator:	Parexel
Start Date:	May 2025
Primary Completion Date:	July 2025
Study Completion Date:	July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, MD	Brooklyn, MD, US, 21225

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.